Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06265766

Brain STimulation for Arm Recovery After Stroke 2

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
454 (estimated)
Sponsor
Jord Vink · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Rationale: Every year, about 40,000 people in the Netherlands have a stroke. After the initial admission to the hospital, about 15% of stroke survivors is admitted to a rehabilitation center because of remaining disabilities. Three out of four of these patients have upper limb dysfunction, hampering activities of daily living. Upper limb function plays a critical role in the performance of most daily life activities. In our phase II trial B-STARS, continuous theta burst stimulation (cTBS) treatment led to an absolute additional recovery of upper limb function of 17%, as measured with the Action Research Arm Test (ARAT) score three months after stroke. This improvement exceeds the minimal clinically important difference of 10%. cTBS treatment also resulted in a significant improvement in measures of activities and participation (of similar magnitude) and a reduction in the mean length of stay at the rehabilitation center by 18 days. Objective: To assess the effectiveness and cost effectiveness of cTBS treatment in promoting upper limb recovery after stroke in patients admitted to a rehabilitation center. Study design: A phase III, multi-center, double-blind, randomized, sham-controlled, clinical trial. Study population: 454 patients aged 18 years or older with a first-ever ischemic stroke or intracerebral hemorrhage and a unilateral arm paresis, defined by a Motricity Index between 9 and 99, in whom cTBS treatment can be started within 3 weeks after stroke onset. Intervention: 10 daily sessions of cTBS delivered over the contralesional primary motor cortex during a period of 2 weeks, delivered immediately before regular care physical therapy of the affected upper limb. Main study parameters/endpoints: The primary endpoint will be the score on the upper extremity section of the Fugl-Meyer assessment (FM-UE) at 90 days after stroke. Secondary endpoints will include the score on the FM-UE at one year and the scores on the Action Research Arm Test, Nine Hole Peg Test, Stroke Impact Scale, EuroQol 5 Dimensions and modified Rankin Scale at 90 days and one year after stroke

Conditions

Interventions

TypeNameDescription
DEVICEActive cTBS10 sessions of active cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
DEVICESham cTBS10 sessions of sham cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.

Timeline

Start date
2024-12-09
Primary completion
2029-03-31
Completion
2029-12-31
First posted
2024-02-20
Last updated
2025-08-27

Locations

16 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06265766. Inclusion in this directory is not an endorsement.